Get the Stockscreener App
16.93
0.29%
-0.05
Theravance Biopharma Inc stock is traded at $16.93, with a volume of 868.22K.
It is down -0.29% in the last 24 hours and up +3.42% over the past month.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
See More
Previous Close:
$16.98
Open:
$17
24h Volume:
868.22K
Relative Volume:
1.65
Market Cap:
$877.45M
Revenue:
$109.78M
Net Income/Loss:
$114.54M
P/E Ratio:
7.6794
EPS:
2.2046
Net Cash Flow:
$268.74M
1W Performance:
+0.00%
1M Performance:
+3.42%
6M Performance:
-11.08%
1Y Performance:
+47.73%
1-Day Range:
$16.91
$17.02
1-Week Range:
$16.91
$17.28
52-Week Range:
$10.82
$21.03
Theravance Biopharma Inc Stock (TBPH) Company Profile
Name
Theravance Biopharma Inc
Sector
Industry
Phone
650-808-6000
Address
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
16.93 | 877.45M | 109.78M | 114.54M | 268.74M | 2.2046 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-26 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-04-26 | Downgrade | B. Riley Securities | Buy → Neutral |
| Dec-03-25 | Initiated | Oppenheimer | Outperform |
| Sep-12-25 | Initiated | B. Riley Securities | Buy |
| Aug-06-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-12-24 | Initiated | BTIG Research | Buy |
| Jan-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-15-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-25-21 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Aug-24-21 | Downgrade | Cowen | Outperform → Market Perform |
| Oct-14-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jun-15-20 | Initiated | Morgan Stanley | Equal-Weight |
| May-13-20 | Initiated | Cowen | Outperform |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-06-19 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Oct-29-19 | Initiated | H.C. Wainwright | Buy |
| Mar-29-18 | Resumed | Piper Jaffray | Overweight |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-17 | Reiterated | Needham | Buy |
| Dec-21-16 | Initiated | Needham | Buy |
| Nov-03-16 | Initiated | Piper Jaffray | Overweight |
| Oct-12-16 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Aug-03-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-20-16 | Initiated | Guggenheim | Buy |
| Jun-20-16 | Reiterated | Leerink Partners | Outperform |
| May-12-16 | Initiated | Leerink Partners | Outperform |
| May-05-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-03-15 | Upgrade | Robert W. Baird | Underperform → Neutral |
View All
Theravance Biopharma Inc Stock (TBPH) Latest News
Liquidity Mapping Around (TBPH) Price Events - Stock Traders Daily
Theravance stock down 3% after Zymeworks announces buyout - MSN
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders - AOL.com
Theravance Biopharma Price Target Raised to $17.00/Share From $15.00 by HC Wainwright & Co. - Moomoo
Zymeworks' $929 Million Pivot: How a COPD Acquisition Redefines Its Future - Kavout | AI
TBPHTheravance Biopharma Inc Options - Finviz
If You Invested $1,000 in Theravance Bioph (TBPH) - Stock Titan
Arthur Cox advises on pharmaceutical sector acquisition - ICLG
Theravance Biopharma Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SurpriseEarnings Season Review - dars.gov.et
TBPH News | THERAVANCE BIOPHARMA INC (NASDAQ:TBPH) - ChartMill
Zymeworks to pay $17/share for Theravance Biopharma in $929M deal - MSN
Theravance Biopharma Insider Sold Shares Worth $5,791,555, According to a Recent SEC Filing - marketscreener.com
Theravance Biopharma Inc (TBPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Theravance Biopharma(TBPH.US) 10% Shareholder Sells US$5.79 Million in Common Stock - Moomoo
Funds tied to Eli Samaha trim Theravance Biopharma (TBPH) stake in open-market sales - Stock Titan
Here’s Why Zymeworks Inc. Paid $929M For Theravance Biopharma (NASDAQ:ZYME) - Seeking Alpha
TBPH SEC FilingsTheravance Bioph 10-K, 10-Q, 8-K Forms - Stock Titan
Arthur Cox advises Theravance Biopharma on its $929 million merger with Zymeworks - Arthur Cox LLP
Zymeworks to Acquire Theravance Biopharma in $929 Million Transaction - Global Legal Chronicle
Canadian Zymeworks acquires American Theravance Biopharma for $929 million - AKM.RU
After a three-decade legacy, Theravance agreed to a complex sale for less than $1 billion - The Business Journals
Theravance Stock Down 3% After Zymeworks Announces Buyout - Yahoo Finance
Press Release: Zymeworks to Acquire Theravance Biopharma, Inc. - Moomoo
Zymeworks agrees to buy Theravance Biopharma for $929m - Pharmaceutical Technology
TBPH Downgraded by BTIG -- Rating Changed to Neutral - GuruFocus
Vancouver biotech Zymeworks buying Theravance for US$929M - Castanet
Zymeworks to Acquire Theravance Biopharma, Inc. - Indovizka.com
Zymeworks Inc to Acquire Theravance Biopharma Inc Transcript - GuruFocus
Zymeworks offers US$929-million for COPD drug maker Theravance - The Globe and Mail
Zymeworks to buy Theravance Biopharma in $929M deal – a look at what this deal means for TBPH shareholders - MSN
Zymeworks Buys Theravance To Execute On New Business Strategy - insights.citeline.com
Theravance Biopharma (TBPH) Downgraded to Hold Following $929M A - GuruFocus
Theravance downgraded at Jones on Zymeworks acquisition - MSN
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareh - GuruFocus
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders? - Finviz
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH) - PR Newswire
TBPH Downgraded by Jones TradingRating Changed to Hold - GuruFocus
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Ther - GuruFocus
Theravance, after clinical setbacks, agrees to $929M buyout - BioPharma Dive
Zymeworks bolsters royalty stream with Theravance buy - BioWorld News
Zymeworks expands beyond cancer with $929 million Theravance acquisition - WTVB
Fair Price or Fast Exit? Scrutiny Mounts Over Theravance Biopharma Sale - BriefGlance
BTIG downgrades Theravance Biopharma stock rating on Zymeworks deal By Investing.com - Investing.com South Africa
Pharma M&A Roundup: Ipsen to Acquire Kartos Therapeutics, Zymeworks to Acquire Theravance Biopharma - Pharmaceutical Executive
BTIG downgrades Theravance Biopharma stock rating on Zymeworks deal - Investing.com
Zymeworks to Acquire Theravance for $929 Million, But Discounted Price Triggers Shareholder Investigation - finance.biggo.com
Zymeworks to acquire Theravance Biopharma for $929M - grafa.com
Zymeworks makes bold move with $929m Theravance Biopharma buy - BioXconomy
Ademi LLP Investigates Whether Theravance Biopharma, Inc. Is Obtaining a Fair Price for Public Shareholders - Moomoo
BTIG Downgrades Theravance Biopharma to Neutral From Buy - Moomoo
Zymeworks Targets Long-Term Cash Generation Through Theravance AcquisitionTheravance Biopharma (NASDAQ - Benzinga
Theravance Biopharma Inc Stock (TBPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Theravance Biopharma Inc Stock (TBPH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Samaha Eli | 10% Owner |
Jul 01 '26 |
Sale |
17.00 |
37,799 |
642,628 |
9,174,453 |
| Samaha Eli | 10% Owner |
Jun 30 '26 |
Sale |
17.13 |
25,027 |
428,788 |
9,212,252 |
| Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS |
Jun 15 '26 |
Sale |
16.39 |
13,314 |
218,167 |
232,457 |
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):